Mylan Finally Nabs Meda In Diversification Play
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal coincides with full year/fourth quarter earnings release.
You may also be interested in...
Deal Watch: Mylan Counts On A Renaissance For Expansion
European markets are the name of the game as Ariad sells its European business to Incyte, Spain's Grupo Ferrer buys out Alexza, Italy's Chiesi bags a suite of CV drugs from The Medicines Co. and Swiss kidney disease specialist Vifor Fresenius takes up Opko's Rayaldee.
Deal Watch: AbbVie Moves Into Microbiome, Synthetic Biology With Synlogic Partnership
Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.
Pharma's Love Affair With Dealmaking: No End In Sight
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.